Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRAL: FTC Conditioning and AlloSCT in Aggressive NHL
NCT04121507Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, thiotepa, cyclophosphamide in non-Hodgkin lymphoma (NHL), sponsored by GWT-TUD. Started Jun 2019; status: completed.
02
Drugs
fludarabinethiotepacyclophosphamide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04121507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121507.